Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 16/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14146298 | 1.00 | CALCRL (0.44) | CALCRLCYP3A4CRBNHTR2AHTR2C | |
| SCHEMBL14146491 | 0.88 | CALCRL (0.46) | CALCRLCYP3A4CRBN | |
| SCHEMBL4223721 | 0.80 | CALCRL (0.66) | CALCRLCYP3A4 | |
| SCHEMBL4223720 | 0.80 | CALCRL (0.66) | CALCRLCYP3A4 | |
| SCHEMBL13062468 | 0.79 | CALCRL (0.39) | CALCRLCYP3A4CRBN | |
| SCHEMBL13747779 | 0.77 | CALCRL (0.38) | CALCRLCYP3A4 | |
| SCHEMBL13792285 | 0.72 | CALCRL (0.70) | CALCRLCYP3A4 | |
| SCHEMBL5095745 | 0.71 | CALCRL (0.70) | CALCRLCYP3A4 | |
| SCHEMBL437043 | 0.70 | CALCRL (0.66) | CALCRLCYP3A4 | |
| SCHEMBL15701571 | 0.70 | CALCRL (0.66) | CALCRLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128375-A1 | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885CYP3A4 1522/4885CRBN 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.